{"Clinical Trial ID": "NCT01365845", "Intervention": ["INTERVENTION 1:", "Conventional photonic plan", "Photon: 50.4 Grey (Gy) breast/vestige wall and peripheral lymph nodes at 1.8 Gy per fraction", "INTERVENTION 2:", "3D-Proton/Conventional Plan or 3D-proton only", "3D-Proton/Conventional plan or 3D-proton only: 50.4 Cobalt Gray Equivalent (CGE)/Gray (Gy) to breast/vestige wall and peripheral lymph nodes at 1.8 CGE/Gy per fraction"], "Eligibility": ["Incorporation criteria:", "Invasive adenocarcinoma of the breast stage I-III (TX, T0-4, N0-3) was confirmed pathologically with a median tumour and/or axillary invasion of the lymph nodes.", "Patients should have undergone breast-preservative mastectomy or surgery.", "Patients are required to have an axillary stage that may include sentinel ganglion biopsy alone if the sentinel ganglion is negative.", "The patient should require peripheral lymphatic radiation at the discretion of the physician.", "- Exclusion criteria:", "Evidence of distant metastases (M1).", "A radiotherapy prior to the area of interest.", "Previous history of cardiovascular disease by doctor discretion.", "A prior or concomitant cancer other than non-melanomatous skin cancer unless the disease is free for at least 5 years.", "A collagen vascular disease, particularly dermatomyosis with a higher than normal level of CPK or with an active skin rash, systemic lupus erythematosis or scleroderma."], "Results": ["Performance measures:", "Volume of heart receiving 5 Gray (Gy)/Cobalt grey equivalent (CGE)", "A 50% reduction in cardiac volume exposed to 5 Gy/CGE radiation doses was considered a preferred outcome in this study design.", "Time limit: 2 weeks before the start of radiation therapy.", "Results 1:", "Title of the arm/group: Conventional photonic plan", "Description of the arm/group: Photon: 50.4 Grey (Gy) at breast/vestige wall and peripheral lymph nodes at 1.8 Gy per fraction", "Total number of participants analysed: 18", "Median (full range)", "Unit of measurement: % of heart receiving >= 5 Gray (Gy) 34.7 (6.9 to 60.0)", "Results 2:", "Title of arm/group: 3D-Proton/Conventional Plan or 3D-proton only", "Description of the arm/group: 3D-Proton/Conventional Plan or only 3D-proton: 50.4 Cobalt Gray Equivalent (CGE)/Gray (Gy) to the breast/vestige wall and peripheral lymph nodes at 1.8 CGE/Gy per fraction", "Total number of participants analysed: 18", "Median (full range)", "Unit of measurement: % of heart receiving >= 5 Gray (Gy) 2.7 (0.1 to 12.3)"], "Adverse Events": ["Undesirable Events 1:", "Total: 6/18 (33.33 per cent)", "- Skin infection [1]2/18 (11.11 %)", "2 [1]4/18 (22.22%)", "Adverse Events 2:", "- Yeah, that's right."]}